CARMAT Completes Enrolment in the EFICAS Clinical Study and Receives Approval From French Authorities for 21 Additional Aeson® Implants, While Awaiting Potential Reimbursement of the Device in France
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the completion of enrolment of the 52 patients planned in the EFICAS study, and the approval from the French authorities to perform 21 additional Aeson® implants, while awaiting potential reimbursement of the device in France.
Stéphane Piat, Chief Executive Officer of CARMA, commented: 'The very strong momentum in the EFICAS study, which enrolment is now complete, reflects the quality and performance of our Aeson® artificial heart and its ability to address the unmet need expressed by healthcare professionals and patients. I am convinced that this study paves the way for strong sales development in Europe and beyond - particularly once its results will have been published, hopefully as soon as end of 2025.
I am also very pleased that, by approving 21 additional implants, the French authorities enable patients in France to continue benefitting from our therapy beyond the EFICAS study. This is a strong sign of confidence in Aeson® artificial heart.
Given the study design, we anticipate to be in a position to file for Aeson®'s reimbursement in France early next year, which could lead to coverage of our artificial heart by the French Social Security system during 2026.
The EFICAS study is also important given our strategy to access the U.S. market, which we are expecting to achieve in 2028.
I would like to thank all patients and healthcare professionals, as well as our teams for their contribution to this important step in Aeson®'s development.'
Enrolment completed in the EFICAS study
Initiated in November 2022, the EFICAS clinical study is the largest ever one conducted by CARMAT. It involves 52 patients eligible for a heart transplant and is carried out across 10 hospitals in France 1.
The primary endpoint of EFICAS is patient survival at 6 months post-Aeson® implant, without disabling stroke, or a successful heart transplant within that period.
EFICAS is key to support Aeson®'s commercial rollout in Europe 2 (through 'evidence-based medicine'), and secure its reimbursement in France, and is also expected to contribute to securing the Pre-Market Approval (PMA) in the United States, currently targeted for 2028 3.
Given the 6-month post-implant follow-up of patients, CARMAT expects completing the EFICAS study (primary endpoint) early November 2025, which will be followed by the publication of its results.
Approval obtained from French authorities for 21 additional Aeson® implants - and filing for reimbursement in France planned early 2026
As a reminder, the EFICAS study is partially funded by the French State (€13 million for 52 implants 4), through the 'Forfait Innovation' program.
In order to allow patients in France to continue benefitting from Aeson® artificial heart after the completion of the 52 implants in the EFICAS study, the French authorities 5 have approved 21 additional implants, under financial terms equivalent to those of the 'Forfait Innovation.
In parallel, CARMAT is taking all necessary steps to be in position to submit a reimbursement application (so-called 'LPPR') for Aeson® at the beginning of 2026, which could allow Aeson® to be covered by the French Social Security system during the same year.
Disclaimer
This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country.
This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT (www.carmatsa.com/en/) and the AMF (www.amf-france.org).
Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today.
Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a few seconds ago
- Business Wire
Clean Jeju Green Tea Cooperative ‘Sumang' to Launch New Hojicha Product This August
BUSINESS WIRE)-- Clean Jeju Green Tea Agricultural Cooperative 'Sumang' has announced that it plans to launch a new product—Hojicha—in August. Hojicha is a roasted green tea made by pan-firing tea leaves at high temperatures, known for its rich, nutty aroma and low caffeine content. 'While we currently focus on B2B transactions, our ultimate goal is to expand into direct-to-consumer channels with a comprehensive distribution network.' Sumang is a vertically integrated producer that grows, processes, and sells organic green tea in Jeju Island. Benefiting from ideal tea-growing conditions—including proximity to the sea, warm temperatures, and frequent mist—the cooperative has been able to cultivate high-quality tea with a consistent moisture supply during the growth period. Recently, global interest in health and wellness has fueled rising demand for matcha, particularly in the United States. Exports have been steadily rising, and inquiries from international buyers are also growing. While many matcha products are flooding the market, consumers often struggle to find high-quality, properly graded matcha. The cooperative's 'Sumang Tea Garden' brand offers matcha in three distinct grades: Ceremonial, Premium, and Superior, giving consumers a variety of options tailored to their taste and intended use. CEO Kyungmin Kang said, 'While we currently focus on B2B transactions, our ultimate goal is to expand into direct-to-consumer channels with a comprehensive distribution network,' adding, 'We are committed to offering high-quality products at affordable prices.' About Sumang Since 2007, Sumang has produced Jeju green tea of the highest quality, provided by the natural environment of Jeju Island, South Korea. Abiding by the strict rules of the Clean Jeju Green Tea Agricultural Cooperative, Sumang offers products that promote both health and environmental sustainability.
Business Wire
a few seconds ago
- Business Wire
Bragg Gaming Group Announces Cyber Security Incident
TORONTO--(BUSINESS WIRE)--Bragg Gaming Group (BRAG:CA) ('Bragg' or the 'Company'), a leading content and technology provider to the online gaming industry, today announced the Company learned of a cybersecurity incident early Saturday morning, August 16, 2025, CEST time. Bragg has taken immediate steps to mitigate any potential impact. Additional independent cybersecurity experts have been retained to assist the Company in dealing with the matter in accordance with industry best practices. Based on preliminary investigations, the Company believes that the data breach was limited to Bragg's internal computer environment. At the present time, there is no indication that any personal information was affected. Additionally, the breach has had no impact on the ability of the Company to continue its operations, nor has it been restricted from accessing any data that has been subject to the breach. Bragg is committed to data safety, is taking the matter very seriously and asks its customers and partners for their patience as it seeks to remediate the situation. The latest information regarding the incident will be made available on and updated as further developments occur. Cautionary Statement Regarding Forward-Looking Information This news release contains forward-looking statements or 'forward-looking information' within the meaning of applicable Canadian securities laws ('forward-looking statements'), including, without limitation, statements with respect to the following: the Company's plans to address the cyber security incident and its expected impact on Bragg's operations and the safety and security of its customers and partners data. Forward-looking statements are provided for the purpose of presenting information about management's current expectations and plans relating to the future and allowing readers to get a better understanding of the Company's anticipated financial position, results of operations, and operating environment. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or describes a 'goal', or variation of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. All forward-looking statements contained in this news release reflect the Company's beliefs and assumptions based on information available at the time the statements were made. Actual results or events may differ from those predicted in these forward-looking statements. All of the Company's forward-looking statements are qualified by the assumptions that are stated or inherent in such forward-looking statements, including the assumptions listed below. Although the Company believes that these assumptions are reasonable, this list is not exhaustive of factors that may affect any of the forward-looking statements. Specifically, the forward-looking statements herein are subject to the risk that the investigation of the cyber security breach is in its initial stages so the assessment of the potential impact could change over time as more information gathered. Forward-looking information, by its very nature, is subject to numerous risks and uncertainties and is based on several assumptions which give rise to the possibility that actual results could differ materially from the Company's expectations expressed in or implied by such forward-looking information and no assurance can be given that any events anticipated by the forward-looking information will transpire or occur, including but not limited to the timing for the investigation and recovery process, the impact on Bragg's business operations, future plans, activities, objectives, operations, strategy, business outlook and financial performance and condition of the Company. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except in accordance with applicable securities laws. About Bragg Gaming Group Bragg Gaming Group (NASDAQ: BRAG, TSX: BRAG) is an iGaming content and turnkey technology solutions provider serving online and land-based gaming operators with its proprietary and exclusive content, and cutting-edge technology. Bragg Studios offer high-performing and passionately crafted casino game titles using the latest in data-driven insights from in-house brands including Wild Streak Gaming, Atomic Slot Lab and Indigo Magic. Its proprietary content portfolio is complemented by a cross section of exclusive titles from carefully selected studio partners under the Powered By Bragg program. Games built on Bragg's remote games server (Bragg RGS) technology are distributed via the Bragg Hub content delivery platform and are available exclusively to Bragg customers. Bragg's flexible, modern, omnichannel Player Account Management (PAM) platform powers multiple leading iCasino and sportsbook brands and at all points is supported by expert in-house managed, operational, and marketing services. Content delivered via the Bragg Hub either exclusively or from the Bragg aggregated games portfolio is managed from a single back-office which is supported by powerful data analytics tools, and Bragg's award-winning FuzeTM player engagement toolset. Bragg is licensed, certified, approved and operational in many regulated iCasino markets globally, including the U.S., Canada, Brazil, United Kingdom, Italy, the Netherlands, Germany, Sweden, Spain, Malta and Colombia. Twitter LinkedIn Facebook Instagram
Business Wire
an hour ago
- Business Wire
EdgeCortix Completes Initial Close of Series B Financing, Driving Total Funding to Nearly $100 Million USD
TOKYO--(BUSINESS WIRE)-- EdgeCortix® Inc., a leading fabless semiconductor company specializing in energy-efficient artificial intelligence (AI) processing at the edge, today announced the initial close of its Series B funding round. This milestone raises EdgeCortix's cumulative funding, including equity investments and substantial non-dilutive government awards since December 2024, to nearly $100 million USD, marking significant momentum in the company's rapid growth and global market expansion. This Series B round attracted substantial interest from prominent global investors, highlighting continued confidence in EdgeCortix's innovative AI technologies, strategic leadership, and robust customer traction. Investors participating in the initial close include Yanmar Ventures, Pacific Bays Capital, NTT Finance Corporation, SiC Power, and Aero X Ventures, along with continued support from existing investors including SBI Investments and Global Hands-On VC (GHOVC). 'The strong support from both new and existing investors is a clear endorsement of our market position and proven success across sectors such as robotics, industrial automation, defense, aerospace, and space exploration,' said Dr. Sakyasingha Dasgupta, Founder and CEO of EdgeCortix. 'This funding empowers us to accelerate the mass-production deployment of our highly successful SAKURA-II AI co-processors, which have secured design-wins across multiple industries. Additionally, it fuels the rapid production of our next-generation SAKURA-X chiplet platform, offering an unprecedented performance of up to 2,000 TOPS per device, with low-power, enabling advanced generative AI workloads in scalable high-performance physical AI systems.' Investor Perspectives: 'We are truly honored to have the opportunity to participate in the investment in EdgeCortix. We believe that the innovative technologies developed by EdgeCortix are closely aligned with Yanmar Ventures' mission to support game-changing solutions that help shape a better future. Through this investment, we look forward to exploring potential collaborations and working together to create value that can be returned to society,' commented Sota Tsutsuki, Senior Capitalist, Yanmar Ventures Co., Ltd. 'We see tremendous potential in EdgeCortix's unique technology, forward-looking market strategy, and proven execution. These strengths position the company to drive meaningful growth in industrial automation, telecommunications, aerospace, and beyond,' added Seiichi Hashimoto, Senior Vice President, Executive Manager, Group Treasury Department, NTT Finance Corporation. 'EdgeCortix is uniquely positioned through the dual-use nature of its technology, underscored by its recent high-profile project award from the U.S. Defense Innovation Unit,' said Maxwell Imai Weiss, Partner, Pacific Bays Capital. 'We see strong potential for significant impact and accelerated growth opportunities across defense, aerospace, and space applications, as well as broader commercial markets,' added Dr. Jason Nye, Partner, Pacific Bays Capital. 'EdgeCortix is exactly what we look for at Aero X Ventures - proven dual-use technology with real traction. They've built energy-efficient AI processors that work across defense, aerospace, and commercial markets, and they're actually winning customers and government contracts. Their recent Defense Innovation Unit award speaks volumes about the strategic value of what they're building,' Management Team, Aero X Ventures. ' Since our initial investment in 2023, EdgeCortix has achieved extraordinary progress. Under the visionary leadership of CEO Dr. Sakyasingha Dasgupta, the team has consistently demonstrated remarkable execution capabilities. This new round of funding will further accelerate their exponential growth - continuous acquisition of new customers, the next generation products development, and keep attracting top-tier talent,' said Ken Yasunaga, Managing Partner, Global Hands-On VC. The Series B funding round remains open, with additional closings anticipated throughout 2025 as global investor interest continues. About EdgeCortix Inc. EdgeCortix is driving innovation in semiconductor solutions for the connected intelligent edge. Established in 2019 and headquartered in Tokyo, Japan, with additional offices in the United States and India, EdgeCortix develops silicon-based, energy-efficient AI processors purpose-built for Generative AI workloads at the edge. The company's patented hardware-software co-design methodology enables highly efficient runtime-reconfigurable AI accelerators, delivering industry-leading performance-per-watt for edge inference across defense, aerospace, smart cities, Industry 4.0, robotics and telecommunications applications.
